Clinical Trials Browser

Bronchiolitis Obliterans Syndrome × Dasatinib × Other hematologic neoplasm × Clear all

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myeloid, Chronic-Phase

NCT01357655 2017-03-14

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Phase 2 Terminated

70 enrolled 8 charts

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia

NCT00349518 2016-02-17

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

Phase 2/3 Withdrawn

LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00103701 2011-04-14

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia

Phase 1 Completed

LymphoidMyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Blast Crisis, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Chronic-Phase, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

SPIRIT2

Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923)

Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced Phase CML or Philadelphia Chromosome Positive ALL

BMS-354825 in Patients With Chronic Accelerated, or Blast Phase Chronic Myelogenous Leukemia or Philadelphia Positive Acute Lymphoblastic Leukemia